Compare NWN & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWN | COAG |
|---|---|---|
| Founded | 1859 | 2020 |
| Country | United States | United States |
| Employees | 1619 | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2018 | 2026 |
| Metric | NWN | COAG |
|---|---|---|
| Price | $49.09 | $30.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $57.40 | ★ $62.67 |
| AVG Volume (30 Days) | 252.5K | ★ 515.7K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | ★ 36.45 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $1,289,363,000.00 | N/A |
| Revenue This Year | $7.33 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $20.76 | ★ N/A |
| Revenue Growth | ★ 11.83 | N/A |
| 52 Week Low | $44.45 | $27.38 |
| 52 Week High | $55.99 | $55.42 |
| Indicator | NWN | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 37.40 |
| Support Level | $48.32 | $28.46 |
| Resistance Level | $50.36 | $33.93 |
| Average True Range (ATR) | 0.78 | 2.32 |
| MACD | 0.27 | 0.43 |
| Stochastic Oscillator | 83.25 | 43.46 |
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.